Mohammed, D., Almukhtar, H. (2025). Comprehensive Approaches to the Effect of Statins on Glucose Homeostasis. , 22(4), 203-214. doi: 10.33899/iraqij.p.2025.155614.1124
Dalya W. Mohammed; Hani M. Almukhtar. "Comprehensive Approaches to the Effect of Statins on Glucose Homeostasis". , 22, 4, 2025, 203-214. doi: 10.33899/iraqij.p.2025.155614.1124
Mohammed, D., Almukhtar, H. (2025). 'Comprehensive Approaches to the Effect of Statins on Glucose Homeostasis', , 22(4), pp. 203-214. doi: 10.33899/iraqij.p.2025.155614.1124
Mohammed, D., Almukhtar, H. Comprehensive Approaches to the Effect of Statins on Glucose Homeostasis. , 2025; 22(4): 203-214. doi: 10.33899/iraqij.p.2025.155614.1124

Comprehensive Approaches to the Effect of Statins on Glucose Homeostasis

Iraqi Journal of Pharmacy
Article 5, Volume 22, Issue 4, December 2025, Pages 203-214    PDF (769.94 K)
Document Type: Review Paper
DOI: 10.33899/iraqij.p.2025.155614.1124
Authors
Dalya W. Mohammed* 1; Hani M. Almukhtar2
1Ninevah Health Directorate, Mosul, Iraq
2Department of Pharmacology and Toxicology, College of Pharmacy, University of Mosul, Mosul, Iraq
Abstract
Background: Disturbance in glucose tolerance  is a significant risk factor for cardiovascular diseases. Statins are commonly prescribed to lower cholesterol levels, but their potential effects on glucose tolerance and induction of type 2 diabetes have drawn attention. Aim: This review highlights the connection between statin medications and glucose homeostasis. Methods: An extensive literature search has been conducted on various electronic databases such as PubMed, Scopus, Web of Science, and Science Direct. Conclusions: Different mechanisms are hypothesized and could be responsible for this pleiotropic effect of statins on glucose homeostasis. Many clinical trials and meta-analyses have reported a significant controversy regarding statins-induced glucose tolerance/intolerance depending on the type of statin and dosage . This urges the researchers to perform more studies to clarify this pleiotropic effect for each statin. Although the present knowledge regarding the impact of statins on glycemic index has been improved, several molecular/cellular aspects are yet to be determined.

Highlights
  • Statins have complex effects on the glucose homeostasis.
  • Different mechanisms of action are responsible for this pleiotropic effect.
  • Some statins negatively impact the glycemic index such as atorvastatin-rosuvastatin- and simvastatin while other statins have an ameliorating effects such as pravastatin.
Keywords
Diabetes; Glucose homeostasis; Insulin resistance; Statins
References
  1. Blais JE, Wei Y, Yap KK, Alwafi H, Ma TT, Brauer R, Lau WC, Man KK, Siu CW, Tan KC, Wong IC, Wei L, Chan EW. Trends in lipid-modifying agent use in 83 countries. Atherosclerosis 2021;328:44-51.
  2. Armitage J. The safety of statins in clinical practice. Lancet 2007;370(9601):1781-1790.
  3. Althanoon Z, Faisal IM, Ahmad AA, Merkhan MM. Pharmacological aspects of statins are relevant to their structural and physicochemical properties. Systematic Reviews in Pharmacy 2020;11(7):167-171.
  4. Stancu C, Sima A. Statins: Mechanism of action and effects. Journal of Cellular and Molecular Medicine 2001;5(4):378-387.
  5. Goldstein JL, Brown MS. Regulation of low-density lipoprotein receptors: Implications for pathogenesis and therapy of hypercholesterolemia and atherosclerosis. Circulation 1987;76(3):504-507.
  6. Ermakova V, Bataev H, Semenenko N. Comparative benefits of statins in coronary heart disease. Journal of Pharmaceutical Negative Results 2021;12(1):7-13.
  7. Alvarez-Jimenez L, Moreno-Cabañas A, Ramirez-Jimenez M, Morales-Palomo F, Ortega JF, Mora-Rodriguez R. Effects of statins and exercise on postprandial lipoproteins in metabolic syndrome vs metabolically healthy individuals. British Journal of Clinical Pharmacology 2021;87(3):955-964.
  8. Climent E, Benaiges D, Pedro-Botet J. Hydrophilic or Lipophilic Statins? Frontiers in Cardiovascular Medicine 2021;8.
  9. Zhang Q, Dong J, Yu Z. Pleiotropic use of statins as non-lipid-lowering drugs. International Journal of Biological Sciences 2020;16(14):2704-2711.
  10. Oesterle A, Laufs U, Liao JK. Pleiotropic Effects of Statins on the Cardiovascular System. Circulation Research 2017;120(1):229-243.
  11. Thompson PD, Panza G, Zaleski A, Taylor B. Statin-associated side effects. Journal of the American College of Cardiology 2016;67(20):2395-2410.
  12. Ramkumar S, Raghunath A, Raghunath S. Statin therapy: Review of safety and potential side effects. Acta Cardiologica Sinica 2016;32(6):631-639.
  13. Kim J, Lee HS, Lee KY. Effect of statins on fasting glucose in non-diabetic individuals: Nationwide population-based health examination in Korea. Cardiovascular Diabetology 2018;17(1).
  14. Millán Núñez-Cortés J, Cases Amenós A, Ascaso Gimilio JF, Barrios Alonso V, Pascual Fuster V, Pedro-Botet Montoya JC, Pintó Sala X, Serrano Cumplido A. Consensus on the Statin of Choice in Patients with Impaired Glucose Metabolism: Results of the DIANA Study. American Journal of Cardiovascular Drugs 2017;17(2):135-142.
  15. Okyay K. Pleiotropic effects of statins: New evidences. Turk Kardiyoloji Dernegi Arsivi 2021;49(7):533-535.
  16. Liao JK, Laufs U. Pleiotropic effects of statins. Annual Review of Pharmacology and Toxicology 2005;45:89-118.
  17. Blum A, Shamburek R. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis 2009;203(2):325-330.
  18. Pedersen TR, Kjekshus J, Berg K, Haghfelt T, Faergeman O, Faergeman G, Pyörälä K, Miettinen T, Wilhelmsen L, Olsson AG, Wedel H. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. Atherosclerosis Supplements 2004;5(3):81-87.
  19. Vidt DG, Cressman MD, Harris S, Pears JS, Hutchinson HG. Rosuvastatin-induced arrest in progression of renal disease. Cardiology 2004;102(1):52-60.
  20. Fauchier L, Clementy N, Babuty D. Statin therapy and atrial fibrillation: Systematic review and updated meta-analysis of published randomized controlled trials. Current Opinion in Cardiology 2013;28(1):7-18.
  21. Pedersen TR, Kjekshus J, Pyörälä K, Olsson AG, Cook TJ, Musliner TA, Tobert JA, Haghfelt T. Effect of Simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). American Journal of Cardiology 1998;81(3):333-335.
  22. Yu W, Zha W, Guo S, Cheng H, Wu J, Liu C. Flos puerariae extract prevents myocardial apoptosis via attenuation oxidative stress in streptozotocin-induced diabetic mice. PLoS ONE 2014;9(5).
  23. Zhu ML, Gao ZT, Lu JX, Wang Y, Wang G, Zhu TT, Li P, Liu C, Wang SX, Yang L. Amorphous nano-selenium quantum dots prevent pulmonary arterial hypertension through recoupling endothelial nitric oxide synthase. Aging 2021;13(3):3368-3381.
  24. Li P, Yin YL, Guo T, Sun XY, Ma H, Zhu ML, Zhao FR, Xu P, Chen Y, Wan GR, Jiang F, Peng QS, Liu C, Liu LY, Wang SX. Inhibition of Aberrant MicroRNA-133a Expression in Endothelial Cells by Statin Prevents Endothelial Dysfunction by Targeting GTP Cyclohydrolase 1 in Vivo. Circulation 2016;134(22):1752-1765.
  25. Park JJ, Yoon M, Cho HW, Cho HJ, Kim KH, Yang DH, Yoo BS, Kang SM, Baek SH, Jeon ES, Kim JJ, Cho MC, Chae SC, Oh BH, Choi DJ. C-reactive protein and statins in heart failure with reduced and preserved ejection fraction. Frontiers in Cardiovascular Medicine 2022;9.
  26. Wang CY, Liao JK. Current advances in statin treatment: From molecular mechanisms to clinical practice. Archives of Medical Science 2007;3(4 SUPPL. A).
  27. Wilmink HW, Twickler MB, Banga JD, Dallinga-Thie GM, Eeltink H, Erkelens DW, Rabelink TJ, Stroes ES. Effect of statin versus fibrate on postprandial endothelial dysfunction: Role of remnant-like particles. Cardiovascular Research 2001;50(3):577-582.
  28. Khatiwada N, Hong Z. Potential Benefits and Risks Associated with the Use of Statins. Pharmaceutics 2024;16(2).
  29. Crisostomo LML, Souza CAM, Mendes CMC, Coimbra SR, Favarato D, Da Luz PL. Vascular and metabolic response to statin in the mildly hypertensive hypercholesterolemic elderly. Clinics 2008;63(5):589-594.
  30. Silva GA, Souza CL, Oliveira M V. Oral glucose tolerance test: Unnecessary requests and suitable conditions for the test. Jornal Brasileiro de Patologia e Medicina Laboratorial 2020;56.
  31. AlDabal L. Metabolic, Endocrine, and Immune Consequences of Sleep Deprivation. The Open Respiratory Medicine Journal 2011;5(1):31-43.
  32. Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, Ostolaza H, Martín C. Pathophysiology of type 2 diabetes mellitus. International Journal of Molecular Sciences 2020;21(17):1-34.
  33. Marathe PH, Gao HX, Close KL. American Diabetes Association Standards of Medical Care in Diabetes 2017. Journal of diabetes 2017;9(4):320-324.
  34. Knutson KL, Spiegel K, Penev P, Van Cauter E. The metabolic consequences of sleep deprivation. Sleep Medicine Reviews 2007;11(3):163-178.
  35. SBPC. Norma PALC.2021. Sociedade Brasileira de Patologia Clínica / Medicina Laboratorial (SBPC/ML) Published online 2021.
  36. Araújo LR, Yafi M, Guimarães FPDM, Takayanagui AMM, Lucena JBDS, Golbert A, Campos MA a., Saúde M da, Sartorelli DS, Franco LJ, Prevenção E, Marcondes J a. M. Sociedade Brasileira de Diabetes. Vol 5.; 2020.
  37. Choudhury AA, Devi Rajeswari V. Gestational diabetes mellitus - A metabolic and reproductive disorder. Biomedicine and Pharmacotherapy 2021;143.
  38. Sunjaya AP, Sunjaya AF, Halim S, Ferdinal F. Risk and Benefits of Statins in Glucose Control Management of Type II Diabetes. International Journal of Angiology 2018;27(3):121-131.
  39. Perego C, Da Dalt L, Pirillo A, Galli A, Catapano AL, Norata GD. Cholesterol metabolism, pancreatic β-cell function and diabetes. Biochimica et Biophysica Acta - Molecular Basis of Disease 2019;1865(9):2149-2156.
  40. O’Keefe JH, Dinicolantonio JJ, Lavie CJ, Bell DSH. The Influence of statins on glucose tolerance and incipient diabetes. US Endocrinology 2014;10(1):68-74.
  41. Cosme P, Rodríguez AB, Garrido M, Espino J. Coping with Oxidative Stress in Reproductive Pathophysiology and Assisted Reproduction: Melatonin as an Emerging Therapeutical Tool. Antioxidants 2023;12(1).
  42. Sasaki J, Iwashita M, Kono S. Statins: Beneficial or adverse for glucose metabolism. Journal of Atherosclerosis and Thrombosis 2006;13(3):123-129.
  43. S. Kostapanos M, L. Liamis G, J. Milionis H, S. Elisaf M. Do Statins Beneficially or Adversely Affect Glucose Homeostasis? Current Vascular Pharmacology 2010;8(5):612-631.
  44. Hammo AA, Althanoon ZA, Ahmad AA. The Protective Effect of Coenzyme Q10 against Doxorubicin-induced Nephrotoxicity in Albino Rats. Revista Electronica de Veterinaria 2022;23(3):314-325.
  45. Ali A, Khalaf M, Ahmad AA. A Comprehensive View on Drugs-Induced Cardiotoxicity and Its Prevention. Iraqi Journal of Pharmacy 2024;0(0):0-0.
  46. Deichmann R, Lavie C, Andrews S. Coenzyme Q10 and statin-induced mitochondrial dysfunction. Ochsner Journal 2010;10(1):16-21.
  47. Brault M, Ray J, Gomez YH, Mantzoros CS, Daskalopoulou SS. Statin treatment and new-onset diabetes: A review of proposed mechanisms. Metabolism: Clinical and Experimental 2014;63(6):735-745.
  48. Samuel VT, Shulman GI. The pathogenesis of insulin resistance: Integrating signaling pathways and substrate flux. Journal of Clinical Investigation 2016;126(1):12-22.
  49. Sattar N, Taskinen MR. Statins are diabetogenic - Myth or reality? Atherosclerosis Supplements 2012;13(1):1-10.
  50. Vikman J, Jimenez‐Feltström J, Nyman P, Eliasson L. Insulin secretion is highly sensitive to desorption of plasma membrane cholesterol. The FASEB Journal 2009;23(1):58-67.
  51. Salunkhe VA, Mollet IG, Ofori JK, Malm HA, Esguerra JLS, Reinbothe TM, Stenkula KG, Wendt A, Eliasson L, Vikman J. Dual Effect of Rosuvastatin on Glucose Homeostasis Through Improved Insulin Sensitivity and Reduced Insulin Secretion. EBioMedicine 2016;10:185-194.
  52. Cederberg H, Stančáková A, Yaluri N, Modi S, Kuusisto J, Laakso M. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. Diabetologia 2015;58(5):1109-1117.
  53. Navarese EP, Buffon A, Andreotti F, Kozinski M, Welton N, Fabiszak T, Caputo S, Grzesk G, Kubica A, Swiatkiewicz I, Sukiennik A, Kelm M, De Servi S, Kubica J. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. American Journal of Cardiology 2013;111(8):1123-1130.
  54. Waters DD, Ho JE, DeMicco DA, Breazna A, Arsenault BJ, Wun CC, Kastelein JJ, Colhoun H, Barter P. Predictors of new-onset diabetes in patients treated with atorvastatin: Results from 3 large randomized clinical trials. Journal of the American College of Cardiology 2011;57(14):1535-1545.
  55. Watts GF, Barrett PHR, Ji J, Serone AP, Chan DC, Croft KD, Loehrer F, Johnson AG. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes 2003;52(3):803-811.
  56. Jaam M, Al-Naimi HN, Haddad MM, Abushanab D, Al-Badriyeh D. Comparative efficacy and safety among high-intensity statins. Systematic Review and Meta-Analysis. Journal of Comparative Effectiveness Research 2023;12(3).
  57. Cui JY, Zhou RR, Han S, Wang TS, Wang LQ, Xie XH. Statin therapy on glycemic control in type 2 diabetic patients: A network meta-analysis. Journal of Clinical Pharmacy and Therapeutics 2018;43(4):556-570.
  58. Sukhija R, Prayaga S, Marashdeh M, Bursac Z, Kakar P, Bansal D, Sachdeva R, Kesan SH, Mehta JL. Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients. Journal of Investigative Medicine 2009;57(3):495-499.
  59. Sattar N, Preiss D, Murray HM. Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Revista Portuguesa de Cardiologia 2010;29(6):1077-1078.
  60. Bernardi A, Rocha VZ, Faria-Neto JR. Use of statins and the incidence of type 2 diabetes mellitus. Revista da Associacao Medica Brasileira Published online 2015.
  61. Luvai A, Mbagaya W, Hall AS, Barth JH. Rosuvastatin: A review of the pharmacology and clinical effectiveness in cardiovascular disease. Clinical Medicine Insights: Cardiology 2012;6:17-33.
  62. Warwick M., Dane A., Raza A, Schneck D. Single- and multiple-dose pharmacokinetics and safety of the new HMG-CoA reductase inhibitor ZD4522. Atherosclerosis 2000;151(1):39.
  63. Martin PD, Mitchell PD, Schneck DW. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. British Journal of Clinical Pharmacology 2002;54(5):472-477.
  64. Abbasi F, Lamendola C, Harris CS, Harris V, Tsai MS, Tripathi P, Abbas F, Reaven GM, Reaven PD, Snyder MP, Kim SH, Knowles JW. Statins Are Associated With Increased Insulin Resistance and Secretion. Arteriosclerosis, Thrombosis, and Vascular Biology 2021;41(11):2786-2797.
  65. Bellia A, Rizza S, Lombardo MF, Donadel G, Fabiano R, Andreadi K, Quon MJ, Sbraccia P, Federici M, Tesauro M, Cardillo C, Lauro D. Deterioration of glucose homeostasis in type 2 diabetic patients one year after beginning of statins therapy. Atherosclerosis 2012;223(1):197-203.
  66. Alvarez-Jimenez L, Morales-Palomo F, Moreno-Cabañas A, Ortega JF, Mora-Rodríguez R. Effects of statin therapy on glycemic control and insulin resistance: A systematic review and meta-analysis. European Journal of Pharmacology 2023;947.
  67. Packard CJ, Boren J, Taskinen MR. Causes and Consequences of Hypertriglyceridemia. Frontiers in Endocrinology 2020;11.
  68. Egan B, Zierath JR. Exercise metabolism and the molecular regulation of skeletal muscle adaptation. Cell Metabolism 2013;17(2):162-184.
  69. Watson RT, Pessin JE. Bridging the GAP between insulin signaling and GLUT4 translocation. Trends in Biochemical Sciences 2006;31(4):215-222.
  70. Karam JG, Loney-Hutchinson L, McFarlane SI. High-dose atorvastatin after stroke or transient ischemic attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. Journal of the cardiometabolic syndrome 2008;3(1):68-69.
  71. Parida S, Swain TR, Routray SN, Maiti R. Effect of atorvastatin on glycaemic parameters in normoglycaemic and prediabetic subjects: A prospective, panel study. Journal of Clinical and Diagnostic Research 2017;11(2):FC04-FC09.
  72. Thongtang N, Tangkittikasem N, Samaithongcharoen K, Piyapromdee J, Srinonprasert V, Sriussadaporn S. Effect of switching from low-dose simvastatin to high-dose atorvastatin on glucose homeostasis and cognitive function in type 2 diabetes. Vascular Health and Risk Management 2020;16:367-377.
  73. Yu Q, Wang F, Meng X, Gong Y, Wang Y, Xu C, Wang S. Short-term use of atorvastatin affects glucose homeostasis and suppresses the expression of LDL receptors in the pancreas of mice. Molecular Medicine Reports 2018;18(3):2780-2788.
  74. Cheng D, Wang Y, Gao S, Wang X, Sun W, Bai L, Cheng G, Chu Y, Zhao S, Liu E. Atorvastatin delays the glucose clearance rate in hypercholesterolemic rabbits. Biomedicine and Pharmacotherapy 2015;72:24-29.
  75. Ferri N, Ruscica M, Fazio S, Corsini A. Low-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative Review. Journal of Clinical Medicine 2024;13(4).
  76. Subhan M, Faryal R, Macreadie I. Exploitation of Aspergillus terreus for the production of natural statins. Journal of Fungi 2016;2(2).
  77. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: A double-blind randomised trial. The Lancet 2010;376(9753):1658-1669.
  78. Chamberlain LH. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Letters 2001;507(3):357-361.
  79. Yada T, Nakata M, Shiraishi T, Kakei M. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet β-cells. British Journal of Pharmacology 1999;126(5):1205-1213.
  80. Razali NR, Huri HZ, Ibrahim L, Vethakkan SR, Abdullah BM. Glycemic effects of simvastatin: Where do we stand? Brazilian Journal of Pharmaceutical Sciences 2018;54(1).
  81. Scattolini V, Luni C, Zambon A, Galvanin S, Gagliano O, Ciubotaru CD, Avogaro A, Mammano F, Elvassore N, Fadini GP. Simvastatin Rapidly and Reversibly Inhibits Insulin Secretion in Intact Single-Islet Cultures. Diabetes Therapy 2016;7(4):679-693.
  82. Paolisso G, Barbagallo M, Petrella G, Ragno E, Barbieri M, Giordano M, Varricchio M. Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis 2000;150(1):121-127.
  83. Panajatovic MV, Singh F, Krähenbühl S, Bouitbir J. Simvastatin impairs glucose homeostasis in mice depending on PGC-1α skeletal muscle expression. Biomedicines 2020;8(9).
  84. Teachey D, Sheen C, Seif AE, Brown VI, Grupp SA. Targeting HMG-CoA Reductase in Acute Lymphoblastic Leukemia (ALL): Statins Inhibit Proliferation and Induce Apoptosis in ALL Cells. Blood 2008;112(11):2927-2927.
  85. Sugiyama S, Fukushima H, Kugiyama K, Maruyoshi H, Kojima S, Funahashi T, Sakamoto T, Horibata Y, Watanabe K, Koga H, Sugamura K, Otsuka F, Shimomura I, Ogawa H. Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease. Atherosclerosis 2007;194(2).
  86. Otani M, Yamamoto M, Harada M, Otsuki M. Effect of long- and short-term treatments with pravastatin on diabetes mellitus and pancreatic fibrosis in the Otsuka-Long-Evans-Tokushima Fatty rat. British Journal of Pharmacology 2010;159(2):462-473.
  87. Yu Y, Ohmori K, Chen Y, Sato C, Kiyomoto H, Shinomiya K, Takeuchi H, Mizushige K, Kohno M. Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model. Journal of the American College of Cardiology 2004;44(4):904-913.
  88. Kaya HK, Demirtas B, Yokus B, Kesim DA, Tasdemir E, Sermet A. Comparative effects of pravastatin and rosuvastatin on carbohydrate metabolism in an experimental diabetic rat model. Acta Pharmaceutica 2024;74(1):117-130.
  89. Chan P, Shao L, Tomlinson B, Zhang Y, Liu ZM. An evaluation of pitavastatin for the treatment of hypercholesterolemia. Expert Opinion on Pharmacotherapy 2019;20(1):103-113.
  90. Frampton JE. Inclisiran: A Review in Hypercholesterolemia. American Journal of Cardiovascular Drugs 2023;23(2):219-230.
  91. Benekos T, Kosmeri C, Vlahos A, Milionis H. Nine-year overview of dyslipidemia management in children with heterozygous familial hypercholesterolemia: A university hospital outpatient lipid clinic project in Northwestern Greece. Journal of Pediatric Endocrinology and Metabolism 2020;33(4):533-538.
  92. Seo WW, Seo SI, Kim Y, Yoo JJ, Shin WG, Kim J, You SC, Park RW, Park YM, Kim KJ, Rhee SY, Park M, Jin ES, Kim SE. Impact of pitavastatin on new-onset diabetes mellitus compared to atorvastatin and rosuvastatin: a distributed network analysis of 10 real-world databases. Cardiovascular Diabetology 2022;21(1).
  93. Abbas S, Khan MN, Samor NA, Abbas H, Khan RP, Kamran J. To Compare the Effects of Pitavastatin on Insulin Resistance in Patients With Type 2 Diabetes Mellitus With Hypercholesterolemia Who Were Previously Being Treated With Atorvastatin. Pakistan Armed Forces Medical Journal 2019;69:S393-S398.
  94. Hussain A, Kaler J, Ray SD. The Benefits Outweigh the Risks of Treating Hypercholesterolemia: The Statin Dilemma. Cureus Published online 2023.
  95. Koh KK, Lim S, Sakuma I, Quon MJ. Caveats to aggressive lowering of lipids by specific statins. International Journal of Cardiology 2012;154(2):97-101.
  96. Zhao W, Zhao SP. Different effects of statins on induction of diabetes mellitus: An experimental study. Drug Design, Development and Therapy 2015;9:6211-6223.
  97. Adams SP, Sekhon SS, Wright JM, Tsang M. Fluvastatin for lowering lipids. Cochrane Database of Systematic Reviews 2016;2016(7).
  98. Sorathia K, Lumbhani A, Chauhan S, Patel M, Soni T, Suhagia BN. Development and Optimization of Fluvastatin Sodium Loaded Biodegradable Microspheres. International Journal of Pharmaceutical Sciences and Drug Research Published online 2023:407-415.
  99. Arampatzis CA, Goedhart D, Serruys PW, Saia F, Lemos PA, De Feyter P. Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention - A Lescol Intervention Prevention Study (LIPS) substudy. American Heart Journal 2005;149(2):329-335.
  100. Preiss D, SRK S, Welsh P, Sattar N, Ray K. Risk of incident diabetes on intensive compared to moderate dose statin therapy: a collaborative meta-analysis of randomized trials. Diabetes 2011;60(SUPPL. 1):A88.
  101. Sonmez A, Dogru T, Tasci I, Yilmaz MI, Pinar M, Naharci I, Bingol N, Kilic S, Demirtas A, Bingol S, Ozgurtas T, Erikci S. The effect of fluvastatin on plasma adiponectin levels in dyslipidaemia. Clinical Endocrinology 2006;64(5):567-572.
  102. Hassan A, Saleem Y, Chaudhry MN, Asghar A, Saleem M, Nawaz S, Syed Q, Iqbal MS, Shahzad K. Optimization of process variables for increased production of lovastatin in Aspergillus terreus PU-PCSIR1 and its characterization. Pakistan journal of pharmaceutical sciences 2019;32(1):363-370.
  103. Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients treated with statins: Population based study. BMJ (Online) 2013;346(7911).
  104. Li J, Ding L, Song B, Xiao X, Qi M, Yang Q, Yang Q, Tang X, Wang Z, Yang L. Emodin improves lipid and glucose metabolism in high fat diet-induced obese mice through regulating SREBP pathway. European Journal of Pharmacology 2016;770:99-109.
  105. Sharkawi SMZ, El-Shoura EAM, Abo-Youssef AM, Hemeida RAM. The potential hepatoprotective effects of lovastatin combined with oral hypoglycemic agents in streptozotocin-induced diabetes in rats. Immunopharmacology and Immunotoxicology 2020;42(2):165-173.
Statistics
Article View: 500
PDF Download: 122


Journal Management System. Powered by iJournalPro.com